Literature DB >> 33552086

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer.

Yinnan Meng1, Wei Wang1, Meng Chen2, Kuifei Chen2, Xinhang Xia1, Suna Zhou1, Haihua Yang1,2.   

Abstract

IDO1-mediated immune escape can lead to the malignant progression of tumors. However, the precise mechanism of IDO1 remains unclear. This study showed that IDO1 can bind to GBP1 and increase the extracellular secretion of IDO1 with the assistance of GBP1, thereby promoting the malignant proliferation and metastasis of lung cancer. In vitro study showed that the high expression levels of IDO1 and GBP1 in lung cancer cells promoted cell invasion and migration. In vivo study revealed that knock-down of IDO1 and GBP1 inhibited tumor growth and metastasis. In addition, Astragaloside IV reduces the extracellular secretion of IDO1 by blocking the interaction of IDO1 and GBP1, thereby reducing T cell exhaustion and inhibiting tumor progression. These results suggest that blocking the extracellular secretion of IDO1 may prevent T cell exhaustion and thereby enhance the effect of PD-1 inhibitors on cancer treatment.
Copyright © 2021 Meng, Wang, Chen, Chen, Xia, Zhou and Yang.

Entities:  

Keywords:  GBP1; PD-1; astragaloside IV; indoleamine 2,3-dioxygenase 1 (IDO1); lung cancer

Year:  2021        PMID: 33552086      PMCID: PMC7857027          DOI: 10.3389/fimmu.2020.622467

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  36 in total

1.  Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival.

Authors:  Debbie M Ferns; Ido P Kema; Marrije R Buist; Hans W Nijman; Gemma G Kenter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

2.  IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Authors:  Ailin Li; Hampartsoum B Barsoumian; Jonathan E Schoenhals; Mauricio S Caetano; Xiaohong Wang; Hari Menon; David R Valdecanas; Sharareh Niknam; Ahmed I Younes; Maria Angelica Cortez; James W Welsh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-21       Impact factor: 7.038

Review 3.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 4.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 5.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2012-10-25       Impact factor: 16.687

Review 6.  Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.

Authors:  Brian W Labadie; Riyue Bao; Jason J Luke
Journal:  Clin Cancer Res       Date:  2018-10-30       Impact factor: 12.531

7.  IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

Authors:  Erik Ladomersky; Lijie Zhai; Alicia Lenzen; Kristen L Lauing; Jun Qian; Denise M Scholtens; Galina Gritsina; Xuebing Sun; Ye Liu; Fenglong Yu; Wenfeng Gong; Yong Liu; Beibei Jiang; Tristin Tang; Ricky Patel; Leonidas C Platanias; C David James; Roger Stupp; Rimas V Lukas; David C Binder; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2018-03-02       Impact factor: 12.531

Review 8.  Cancer immunoediting and resistance to T cell-based immunotherapy.

Authors:  Michele W L Teng; Mark J Smyth; Jake S O'Donnell
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

9.  Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1.

Authors:  Rita Romani; Irene Pirisinu; Mario Calvitti; Maria Teresa Pallotta; Marco Gargaro; Giovanni Bistoni; Carmine Vacca; Alessandro Di Michele; Ciriana Orabona; Jessica Rosati; Matteo Pirro; Stefano Giovagnoli; Davide Matino; Paolo Prontera; Gabriella Rosi; Ursula Grohmann; Vincenzo N Talesa; Emilio Donti; Paolo Puccetti; Francesca Fallarino
Journal:  J Cell Mol Med       Date:  2015-03-17       Impact factor: 5.310

10.  Detection of Cytosolic Shigella flexneri via a C-Terminal Triple-Arginine Motif of GBP1 Inhibits Actin-Based Motility.

Authors:  Anthony S Piro; Dulcemaria Hernandez; Sarah Luoma; Eric M Feeley; Ryan Finethy; Azeb Yirga; Eva M Frickel; Cammie F Lesser; Jörn Coers
Journal:  mBio       Date:  2017-12-12       Impact factor: 7.867

View more
  2 in total

1.  Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma.

Authors:  Xin Wang; Weihao Lin; Tiejun Liu; Zhenyi Xu; Zhen Wang; Zheng Cao; Xiaoli Feng; Yibo Gao; Jie He
Journal:  Transl Lung Cancer Res       Date:  2021-12

Review 2.  Kynurenines as a Novel Target for the Treatment of Malignancies.

Authors:  Adrian Mor; Anna Tankiewicz-Kwedlo; Dariusz Pawlak
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.